Key Takeaways:
EyePoint Pharmaceuticals (EYPT) has initiated legal action against Ocular Therapeutix (OCUL) in a Massachusetts federal court. The lawsuit accuses Ocular of making false statements about its lead drug candidate, Duravyu, which is in late-stage trials for eye conditions like wet age-related macular degeneration. EyePoint seeks an injunction to halt these claims, a retraction, and financial compensation. Both companies' treatments are tyrosine kinase inhibitors, with Ocular's Axpaxli targeting similar conditions.
EyePoint Inc is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, potentially reducing the frequency of follow-up care. The company's pipeline includes DURAVYU, a sustained-release product candidate for retinal diseases, and EYP-2301, an early-stage program using Durasert E technology. EyePoint operates within the healthcare sector, specifically in the biotechnology industry, with a market capitalization of approximately $1.1 billion.
Over $50 million grabbed over from Pfizer kickback scheme involving migraine drug “Nurtec” From U.S Attorney’s Office for the Western District of NY BUFFALO, N.Y. – U.S. Attorney Michael DiGiacomo...